Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Instituto Sanitas and Chemopharma are Chilean pharmaceutical laboratories with more than a century of combined experience in the development, manufacturing and commercialization of medicines for the local healthcare market. Founded in the early 20th century, the companies have built a diversified portfolio of over 150 pharmaceutical products across multiple therapeutic areas, including cardiology, neuropsychiatry, analgesics and other treatments. They serve a broad network of customers through retail pharmacies, hospitals, clinics and public health institutions across Chile, positioning themselves as long-standing suppliers within the national pharmaceutical industry.
Laboratorios Saval is a Chilean pharmaceutical company with more than 85 years of experience in the development, manufacturing and commercialization of medicines and healthcare products. Founded in the late 1930s and headquartered in Santiago, the company has established itself as a leading player in the Chilean pharmaceutical market through a diversified product portfolio, modern manufacturing facilities and long-standing relationships with healthcare professionals and institutions. The company has also developed a significant regional footprint, with operations and commercial presence across more than 14 countries in Latin America, supported by subsidiaries, distributors, and production capabilities in the region.
The sellers are part of a Chilean conglomerate with a significant presence across multiple sectors, including agriculture, pharmaceuticals and real estate.
Oaklins’ team in Chile acted as the sole financial advisor in the transaction.
Talk to the deal team
Related deals
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreClinical Partners has raised new debt facilities
Clinical Partners Ltd. has successfully restructured and upsized its debt facilities to better reflect the scale of the business. The company increased its original US$9.4 million facility, comprising a US$3.4 million term loan and a US$6 million revolving credit facility (RCF), to a US$27 million RCF.
Learn more